Vantage Investment Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

Vantage Investment Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$140K	Buy	250 +40	+19%	+$23.9K	0.03%	180
2018 Q2	$140K	Hold	210	–	–	0.03%	176
2018 Q1	$114K	Hold	210	–	–	0.03%	183
2017 Q4	$113K	Buy	210 +20	+11%	+$12.6K	0.03%	189
2017 Q3	$136K	Buy	190 +20	+12%	+$16.4K	0.04%	164
2017 Q2	$149K	Hold	170	–	–	0.04%	148
2017 Q1	$99K	Hold	170	–	–	0.03%	178
2016 Q4	$57K	Hold	170	–	–	0.02%	232
2016 Q3	$62K	Hold	170	–	–	0.03%	220
2016 Q2	$60K	Hold	170	–	–	0.03%	234
2016 Q1	$63K	Hold	170	–	–	0.03%	220
2015 Q4	$67K	Hold	170	–	–	0.03%	206
2015 Q3	$62K	Buy	+170	New	+$69.5K	0.04%	206

Other funds holding SCNI

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

BHB

Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vantage Investment Advisors's SCNI Position: Q3 2018 in Review

Vantage Investment Advisors increased its Scinai Immunotherapeutics (SCNI) stake by 19% in Q3 2018, buying an estimated $23.9K and bringing the position to 250 shares worth $140K. The position accounts for 0.03% of the portfolio, ranked #180.

Vantage Investment Advisors first reported a position in SCNI in Q3 2015 and has held it in 13 quarters since. The position peaked at $149K in Q2 2017. 11 funds tracked by Wall St. Rank hold SCNI as of Q3 2018.

Vantage Investment Advisors held 250 shares of Scinai Immunotherapeutics worth $140K as of Q3 2018.
Vantage Investment Advisors bought 40 Scinai Immunotherapeutics shares in Q3 2018, an estimated $23.9K.
Scinai Immunotherapeutics made up 0.03% of Vantage Investment Advisors's portfolio in Q3 2018, its #180 holding.
Vantage Investment Advisors first reported a position in Scinai Immunotherapeutics in Q3 2015 and has held it in 13 quarters since.
Vantage Investment Advisors's Scinai Immunotherapeutics position peaked at $149K in Q2 2017.
11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.